EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders

Chung-Lin Lee iD, Ya-Hui Chang, Chih-Kuang Chuang iD, Huei-Ching Chiu, Yuan-Rong Tu, Yun-Ting Lo, Jun-Yi Wu, Hsiang-Yu Lin iD, Shuan-Pei Lin

International Journal of Molecular Sciences · 2026

DOI: 10.3390/ijms27052446 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Chung-Lin Lee und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, MacKay Memorial Hospital, Taipei 104217, Taiwan. Hauptthemen laut MEDLINE: Exome Sequencing, Muscular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mackay Memorial Hospital, National Science and Technology Council, Taiwan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Muscle biopsy has long been regarded as the cornerstone for diagnosing pediatric muscular disorders; however, it is invasive and may be limited by sampling error and inconclusive histopathological findings. This study aimed to evaluate whether whole-exome sequencing (WES) can effectively replace muscle biopsy as a first-line diagnostic approach in children with suspected neuromuscular disorders. Between January 2018 and December 2025, we prospectively enrolled 47 pediatric patients presenting with clinical features suggestive of muscular disorders at a tertiary medical center in Taiwan. The cohort included patients with suspected muscular dystrophies (n = 21), congenital myopathies (n = 23), and multiplex ligation-dependent probe amplification (MLPA)-negative Duchenne muscular dystrophy (DMD; n = 3). All patients underwent WES as the initial diagnostic test without prior muscle biopsy. Trio-based analysis using parental samples was performed in 29.8% of cases. Variant interpretation followed the American College of Medical Genetics and Genomics (ACMG) guidelines. WES identified a definitive molecular diagnosis in 72.3% of patients (34/47). Diagnostic yields varied by subgroup: 100% (3/3) in MLPA-negative DMD, 71.4% (15/21) in muscular dystrophies, and 69.6% (16/23) in congenital myopathies. Pathogenic or likely pathogenic variants were detected in 31 distinct genes, including COL6A1 and COL6A3, which are associated with Ullrich congenital muscular dystrophy. Notably, 58.8% of diagnosed patients (20/34) received molecular diagnoses that differed from their initial clinical impression, encompassing conditions such as ZSWIM6-associated neurodevelopmental disorders, GJB2-related hearing loss, OCRL-associated Lowe syndrome, and various metabolic or syndromic disorders. In all three MLPA-negative DMD cases, WES identified point mutations amenable to mutation-specific therapies. No patient required a muscle biopsy for diagnostic confirmation during the study period. First-tier WES demonstrates high diagnostic utility in pediatric muscular disorders while avoiding invasive muscle biopsy. The high rate of diagnostic reclassification underscores the substantial phenotypic overlap between primary neuromuscular diseases and other neurological or systemic conditions. These findings support the early implementation of genetic testing to enable accurate diagnosis and timely initiation of targeted therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Exome SequencingMuscular DiseasesHumansMaleFemaleChild, PreschoolChildBiopsyInfantAdolescentMuscular DystrophiesMutationTaiwan

Stichwörter der Autor:innen

congenital myopathydiagnostic yieldmuscle biopsymuscular dystrophywhole-exome sequencing

Autor:innen und Institutionen

  • Department of Pediatrics, MacKay Memorial Hospital, Taipei 104217, Taiwan.
  • Institute of Clinical Medicine, National Yang-Ming Chiao-Tung University, Taipei 112304, Taiwan.
  • International Rare Disease Center, MacKay Memorial Hospital, Taipei 104217, Taiwan.
  • Department of Medicine, Mackay Medical University, New Taipei City 252005, Taiwan.
  • Department of Nursing, Mackay Junior College of Medicine, Nursing and Management, New Taipei City 252005, Taiwan.
  • Division of Genetics and Metabolism, Department of Medical Research, MacKay Memorial Hospital, Taipei 104217, Taiwan.

ORCID-Profile: Chung-Lin Lee, Chih-Kuang Chuang, Hsiang-Yu Lin

Förderung

  • Mackay Memorial Hospital
  • National Science and Technology Council, Taiwan

Zitieren

APA

Lee, C. L., Chang, Y. H., Chuang, C. K., Chiu, H. C., Tu, Y. R., Lo, Y. T., Wu, J. Y., Lin, H. Y., & Lin, S. P. (2026). Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27052446

Vancouver

Lee CL, Chang YH, Chuang CK, Chiu HC, Tu YR, Lo YT, et al. Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27052446

BibTeX
@article{Lee2026,
  author = {Lee, Chung-Lin and Chang, Ya-Hui and Chuang, Chih-Kuang and Chiu, Huei-Ching and Tu, Yuan-Rong and Lo, Yun-Ting and Wu, Jun-Yi and Lin, Hsiang-Yu and Lin, Shuan-Pei},
  title = {Skipping the Biopsy: Real-World Experience of Whole-Exome Sequencing as First-Tier Testing in Pediatric Muscular Disorders},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  doi = {10.3390/ijms27052446}
}
Kostenlos starten →